Dashboard
Manage Tickers

IMMPIMMUTEP Ltd

Nasdaq immutep.com


$ 1.88 $ 0.04 (2.19 %)    

Wednesday, 07-Aug-2024 15:59:25 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 431.72 $ -4.76 (-1.08 %)
DIA $ 387.79 $ -2.19 (-0.56 %)
SPY $ 518.50 $ -3.49 (-0.67 %)
TLT $ 95.87 $ -0.68 (-0.7 %)
GLD $ 220.55 $ -0.15 (-0.07 %)
$ 1.87
$ 1.86 x 100
-- x --
-- - --
$ 1.58 - $ 3.34
165,379
na
222.03M
$ 0.73
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

abbott-integra-lifesciences-and-other-big-stocks-moving-lower-in-mondays-pre-market-session
Abbott, Integra LifeSciences And Other Big...
07/29/2024 12:24:00

immutep-announces-successful-meeting-with-fda-on-phase-iii-design-in-non-small-cell-lung-cancer-tacti-004-registrational-trial-will-enrol-750-patients-regardless-of-pd-l1-expression-in-order-to-address-the-entire-1l-nsclc-market-eligible-for-anti-pd-1-therapy
Immutep Announces Successful Meeting With ...
07/22/2024 12:03:25

Final discussion with the FDA, successfully concluding the regulatory preparations for the TACTI-004 Phase III trial design to ...

immutep-receives-regulatory-clearance-for-phase-i-study-of-first-in-class-lag-3-agonist-antibody-designed-to-treat-autoimmune-diseases
Immutep Receives Regulatory Clearance For ...
07/17/2024 12:07:24

Study expected to enrol first participants during Q3 CY2024 SYDNEY, AUSTRALIA, July 17, 2024 (GLOBE NEWSWIRE) -- Immutep Limite...

why-asp-isotopes-shares-are-trading-lower-by-9-here-are-other-stocks-moving-in-fridays-mid-day-session
Why ASP Isotopes Shares Are Trading Lower ...
07/12/2024 17:14:56

Core News & Articles
Market-Moving News for July 12th
07/12/2024 12:37:11

ZAPP: 40% | Zapp Electric Vehicles shares are trading higher after the company announced that it entered into a new standby equ...

australia-based-cancer-focused-immuteps-lead-cancer-drug-shows-meaningful-response-in-untreated-head--neck-cancer-stock-soars
Australia Based Cancer Focused Immutep's L...
07/12/2024 11:39:58

Immutep announces results from Cohort B of the TACTI-003 Phase 2b trial. The combination of eftilagimod alfa and Merck's Ke...

why-ericsson-shares-are-trading-higher-here-are-20-stocks-moving-premarket
Why Ericsson Shares Are Trading Higher; He...
07/12/2024 09:35:41

reported-earlier-immutep-announces-results-for-first-line-treatment-of-head-and-neck-squamous-cell-carcinoma-patients-with-negative-pd-l1-expression
Reported Earlier, Immutep Announces Result...
07/12/2024 07:34:02

Efti in combination with KEYTRUDA® (pembrolizumab) achieved a 35.5% response rate in evaluable patients (N=31), according to ...

levi-strauss-posts-mixed-results-joins-walgreens-aerovironment-and-other-big-stocks-moving-lower-in-thursdays-pre-market-session
Levi Strauss Posts Mixed Results, Joins Wa...
06/27/2024 12:33:51

baird-maintains-outperform-on-immutep-lowers-price-target-to-6
Baird Maintains Outperform on Immutep, Low...
06/27/2024 11:09:35

Baird analyst Joel Beatty maintains Immutep (NASDAQ:IMMP) with a Outperform and lowers the price target from $7 to $6.

immutep-and-cardiff-university-sign-exclusive-license-for-next-generation-anti-lag-3-molecules-for-cancer
Immutep And Cardiff University Sign Exclus...
06/25/2024 12:14:11

Immutep Limited ((ASX: IMM, NASDAQ:IMMP) ("Immutep" or "the Company"), a clinical-stage biotechnology company d...

trading-halt-halt-status-updated-at-70000-am-et-quotation-resumption-news-and-resumption-times
Trading Halt: Halt status updated at 7:00:...
06/05/2024 11:00:05

trading-halt-halted-at-35850-am-et---trading-halt-halt-news-pending
Trading Halt: Halted at 3:58:50 a.m. ET - ...
06/03/2024 07:58:54

reported-earlier-immutep-teams-up-with-msd-to-test-efti-and-keytruda-combination-in-phase-iii-non-small-cell-lung-cancer-trial
Reported Earlier, Immutep Teams Up With MS...
06/03/2024 05:45:56

Phase III collaboration will evaluate efti in combination with KEYTRUDA, MSD's anti-PD-1 therapy, and standard chemothera...

capital-one-initiates-coverage-on-immutep-with-overweight-rating-announces-price-target-of-10
Capital One Initiates Coverage On Immutep ...
05/17/2024 15:13:45

Capital One analyst Naureen Quibria initiates coverage on Immutep (NASDAQ:IMMP) with a Overweight rating and announces Price...

earlier-immutep--data-from-safety-lead-in-phase-of-aipac-003-confirmed-complete-response-in-a-patient-with-metastatic-breast-cancer-refractory-to-several-lines-of-therapy-achieved-during-combination-treatment-with-90mg-efti-and-paclitaxel
Earlier: Immutep Data From Safety Lead-in...
05/15/2024 09:17:49

– Immutep Limited ((ASX: IMM, NASDAQ:IMMP) (“Immutep” or “the Company”), a clinical-stage biotechnology company developing nove...

initial-clinical-data-reported-from-immuteps-efti-combined-with-radiotherapy-and-checkpoint-inhibitor-from-phase-ii-trial-in-soft-tissue-sarcoma
Initial Clinical Data Reported From Immute...
05/02/2024 12:07:35

Novel triple combination of efti with radiotherapy and anti-PD-1 therapy is well tolerated and has led to encouraging initial e...

immutep-reported-cash-cash-equivalent-balance-of-954m-as-of-march-31-2024-giving-it-expected-cash-reach-into-early-cy2026
Immutep Reported Cash, Cash Equivalent Bal...
04/29/2024 09:24:22

12-health-care-stocks-moving-in-wednesdays-intraday-session
12 Health Care Stocks Moving In Wednesday'...
04/24/2024 16:31:39

why-australian-cancer-biotech-firm-immutep-stock-is-soaring-on-wednesday
Why Australian Cancer Biotech Firm Immutep...
04/24/2024 14:43:20

Immutep releases preliminary results from TACTI-003 trial showing promising outcomes for first-line treatment of HNSCC patients...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION